Foundation / Corporation
Israel Cancer Research Fund (ICRF)
01/17/18 11:59 PM ET Receipt
Grants providing a stipend of $60,000 per year to Israel established medical researchers employed at a qualifying institution for research addressing the diagnosis, treatment, biology, and prevention of ovarian cancer, as well as uterine/MMMT cancer. Funding may be requested for clinical, basic, or translational research. Research must be conducted in Israel.
Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth leading cause of cancer death among American women. Early detection is rarely possible, and only 20 percent of ovarian tumors are localized at the time of presentation. Uterine cancer is the most commonly diagnosed gynecologic cancer and the fourth most diagnosed cancer of women in the United States. MMMT (malignant mixed mullerian tumor) is an unusual tumor, typically occurring in the uterus, that contains a mixture of malignant epithelial and mesenchymal tissues. MMMT is an aggressive neoplasm that has an extremely poor prognosis. For these reasons, determining risk factors (genetic, environmental and gene-environment interactions), developing preventive strategies, improving detection technologies, and devising new strategies for targeted treatment of ovarian and uterine/MMMT tumors are very important goals for cancer research.
The ICRF has always been committed to supporting world-class cancer research that contributes to improved cancer treatment and can lead to cancer cures. Graciously supported by Len and Susan Mark, this special ICRF research grant initiative has been established to advance our knowledge of the pathogenesis and treatment of Ovarian and Uterine/MMMT Cancers. While not a requirement, grants that utilize interdisciplinary approaches and that are multi-investigator are encouraged.
GrantWatch ID#: 182706
The funding level will be approximately $60,000 per year ($180,000 total stipend).
Awarded grants will be for a period of three (3) years. Progress reports will be due after the first and second years. Continued funding is not automatic, but will be contingent upon acceptable progress. A progress report reminder notice, along with forms and instructions, will be sent out in advance of the due date.
Awards will be activated September 1, 2018.
The Len and Susan Mark Initiative for Ovarian, and Uterine/MMMT Cancers grants are intended to support the research of established investigators studying the biology, diagnosis, treatment, or prevention of ovarian and/or uterine/MMMT cancers. Grants will be made to an institution or cooperating institutions with the understanding that they will support a specific project under the direction of a designated principal investigator. ICRF support is given only to Israeli institutions for work in Israel.
Funds for cancer research are available to citizens of Israel, both native-born and those who have settled. Funds are not available to visiting scientists. (Proof of Israeli citizenship must be furnished upon request.)
The funds are to be used for actual direct expenses (salary, supplies, etc.) connected with the project. No overhead, clerical or other administrative charges may be made by the institution against the award funds. ICRF does not allow funds to be used for travel.
The application deadline is January 17, 2018, at 11:59 PM ET.
-Application Received by the Fund in New York: January 17, 2018
-Notification of Decision: July 1, 2018
-Activation of Award: September 1, 2018
Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.
Register to apply:
Ellen T. Rubin, Director, Research Grants
Israel Cancer Research Fund
52 Vanderbilt Avenue, Suite 1510
New York, NY 10017-3834